Sobi to present new data at ASH 2023 Annual Meeting Nov 20, 2023 02:36AM
U.S. Food and Drug Administration Issues Emergency Use Authorization for KINERET® (anakinra) for the Treatment of COVID-19-Related Pneumonia Nov 10, 2022 07:00AM
Sobi to license loncastuximab tesirine from ADC Therapeutics Jul 8, 2022 02:59AM
ADC Therapeutics Announces Exclusive License Agreement with Sobi to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Europe and Select International Territories Jul 8, 2022 02:00AM
Sobi Announces Launch of the INTO-HLH Registry, a Disease Registry for Patients with Hemophagocytic Lymphohistiocytosis (HLH) Jun 28, 2022 08:00AM


Jun 10, 2022 03:00AM Apellis and Sobi Report New Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI® (pegcetacoplan) for PNH at EHA 2022 Congress
Jun 7, 2022 07:00AM Apellis and Sobi Announce First Patient Dosed in Phase 3 VALIANT Study of Pegcetacoplan for IC-MPGN and C3G, Rare Kidney Diseases with High Unmet Medical Need
Dec 1, 2018 12:00PM At ASH, Extended Half-Life Therapies ELOCTATE® and ALPROLIX® Demonstrate Proven Efficacy and Well-Characterized Safety over Four Years
Dec 11, 2017 10:02AM New Data Show Extended Prophylactic Dosing with ALPROLIX® Provides Safe and Effective Protection in People with Severe Hemophilia B
Dec 10, 2017 09:02AM Study Shows Weekly Prophylactic Treatment with ELOCTATE® Resulted in Bleed Protection and Target Joint Resolution in People with Hemophilia A
Jul 6, 2017 07:00AM Bioverativ and Sobi Highlight Commitment to Improving Care for People with Hemophilia at ISTH 2017 Congress
Mar 2, 2017 07:05AM Bioverativ (BIVV), Sobi Announced Published Long-term Safety and Efficacy Extension Study Data of ALPROLIX
Mar 2, 2017 07:00AM Long-term Safety and Efficacy Extension Study Data of ALPROLIX® for Hemophilia B Published in Thrombosis and Haemostasis
Feb 2, 2017 07:46AM Swedish Orphan Biovitrum AB - Long-term Safety and Efficacy Data of Extended Half-life Therapy Alprolix in Children With Haemophilia B Published in The Lancet Haematology
Feb 2, 2017 07:30AM Long-Term Safety and Efficacy Data of Extended Half-Life Therapy ALPROLIX® in Children with Hemophilia B Published in The Lancet Haematology
Feb 1, 2017 03:09AM Sobi and Bioverativ to Reveal new Long-term Safety and Efficacy Data of Elocta® and Alprolix® at EAHAD
Dec 7, 2016 07:40AM Horizon Pharma (HZNP), Sobi Enter Ravicti, Ammonaps Distribution Agreement
Dec 7, 2016 07:36AM Sobi and Horizon Pharma enter five-year distribution agreement for Ravicti® and Ammonaps® outside the United States
Dec 5, 2016 07:04AM Biogen (BIIB), Sobi Announce Presentation of ELOCTATE, ALPROLIX Data at ASH 2016
Dec 3, 2016 07:00AM Data Reinforcing the Long-Term Safety and Efficacy of Extended Half-Life Hemophilia Therapies ELOCTATE® and ALPROLIX® Highlighted at 58th ASH Meeting
Jul 18, 2016 07:32AM Biogen (BIIB), Sobi to Present Updated ELOCTATE Data at Hemophilia 2016 World Congress
Jul 18, 2016 07:30AM Biogen and Sobi to Showcase Long-Term Efficacy and Safety Data from Extended Half-Life Hemophilia Therapies at World Federation of Hemophilia 2016 World Congress
May 13, 2016 06:47AM Biogen (BIIB), Sobi Announce EC Approval of Alprolix as Haemophilia B Treatment
May 13, 2016 02:47AM Alprolix® (rFIXFc) Approved in the EU for the Treatment of Haemophilia B
Feb 26, 2016 07:11AM Sobi and Biogen Receive Positive Opinion from CHMP for Alprolix® (rFIXFc) for the Treatment of Hemophilia B
Dec 8, 2015 07:02AM Biogen (BIIB), Sobi Present Positive Data on ELOCTATE, ALPROLIX in Hemophilia A and B
Dec 8, 2015 07:00AM New Data Show ELOCTATE® and ALPROLIX® May Help Control Target Joint Bleeds in People with Hemophilia A and B
Nov 24, 2015 02:00AM Sobi and Biogen’s ELOCTA® (rFVIIIFc) Approved in Europe for the Treatment of Haemophilia A